RxDoctor Payments DataLook up a doctor →

Ivan Mac, MD

Ophthalmology · Monroe, NCNPI 1689654592

Payments from drug & device makers

$258,270in general payments, 2019–2025

Across 621 payments — averaging $415.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon Research LLC$155K
  • Alcon$48K
  • Kala Pharmaceuticals, Inc.$11K
  • Tearlab Corp$11K
  • Johnson & Johnson Surgical Vision, Inc.$9K
  • Eyevance Pharmaceuticals LLC$9K
  • plus $16K from 31 others

What the payments were for

  • Consulting fees$52,66351%
  • Speaking & faculty fees$15,57615%
  • Travel & lodging$5,8766%
  • Food & beverage$29,85629%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$258,270 in reported general payments places this provider in the 95th percentile of 588 ophthalmology providers in North Carolina.

See all ophthalmology providers in North Carolina

Medicare billing

Part B allowed, 2024
$561,918
Medicare patients
1,108
Services billed
6,363

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine191$235,740
XiidraLifitegrast124$169,130
XdemvyLotilaner75$138,957
VevyeCyclosporine64$56,148
TyrvayaVarenicline Tartrate52$39,016
Cyclosporine39$21,187
VyzultaLatanoprostene Bunod19$11,238
IlevroNepafenac26$9,611
CequaCyclosporine11$9,482
RocklatanNetarsudil Mesylat/Latanoprost11$7,677
Prednisolone Acetate117$4,474
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol30$3,568
Latanoprost313$3,420
Loteprednol Etabonate16$1,915
FlarexFluorometholone Acetate12$1,511

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis$1,585$235,740191 claims
Bausch & Lomb Americas Inc.Xiidra, Vyzulta$1,008$180,367143 claims
Tarsus Pharmaceuticals, Inc.Xdemvy$797$138,95775 claims
Harrow Eye, LLCVevye$1,148$56,14864 claims
Oyster Point Pharma, Inc.Tyrvaya$579$39,01652 claims
NovartisIlevro$1,039$9,61126 claims
Sun Pharmaceutical Industries Inc.Cequa$705$9,48211 claims
Aerie Pharmaceuticals, Inc.Rocklatan$131$7,67711 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate$875$1,91516 claims
Eyevance Pharmaceuticals LLCFlarex$9,196$1,51112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 588 ophthalmology providers in North Carolina.

Other ophthalmology in Monroe

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →